CD274 and cancer: It was developed to use gene expression profiles of cancer samples to predict response to ICI by reporting on both immune and stromal cellular elements, a tissue agnostic interferon gamma signature, as well as the enrichment scores of ICI biomarkers, microsatellite instability and PD-L1, among others (210).